E
Exact Therapeutics AS
OSE:EXTX
Exact Therapeutics AS
OSE:EXTX
Price:
1.66
NOK
3.11%
Market Closed
Market Cap:
kr105m
Relative Value
There is not enough data to reliably calculate the relative value of EXTX.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
EXTX
Relative Value
Base Case
Not Available
Multiples Across Competitors
EXTX Competitors Multiples
Exact Therapeutics AS Competitors
Exact Therapeutics AS Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| NO |
E
|
Exact Therapeutics AS
OSE:EXTX
|
105m NOK | 0 | -1.5 | -0.7 | -0.7 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
409.6B USD | 6.8 | 171.5 | 16.6 | 23.5 | |
| US |
|
Astria Therapeutics Inc
NASDAQ:ATXS
|
326.4B USD | 462 374.5 | -2 631.9 | -2 389.6 | -2 389.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
208.3B USD | 5.6 | 26.8 | 15.3 | 15.3 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
184.3B USD | 6.2 | 21.6 | 14.6 | 14.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
124.4B USD | 10.2 | 31.1 | 23.8 | 24.8 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
83.3B USD | 5.8 | 18.5 | 14 | 16 | |
| NL |
|
argenx SE
XBRU:ARGX
|
43.3B EUR | 14.3 | 33.5 | 57.4 | 59 | |
| AU |
|
CSL Ltd
ASX:CSL
|
70.2B AUD | 3.2 | 16.5 | 11.3 | 14.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
